#Drug Formulation Market

[bhushans]

Meeting the Needs of a Growing Population: The Evolving Global Drug Formulation Market

The global Drug Formulation market is projected to increase between 2022 and 2032 at a compound annual growth rate of 5.6%. Sales of medication formulations are predicted to reach USD 1.58 trillion by 2022. The study projects that during the forecast period, oral formulations would develop at an exponential rate, with a compound annual growth rate of 6.0%.

Enhance Research With a Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-15755

The worldwide drug formulation market is crucial to the pharmaceutical industry because it facilitates the transformation of active pharmaceutical ingredients (APIs) into finished pharmaceuticals that are safe for ingestion by humans. The expected growth is due to both the growing demand for pharmaceutical items and advancements in medicine formulation technology.

Key Takeaways:

The global drug formulation market is expected to reach US$2.87 trillion by 2032, growing at a CAGR of 5.6%.

Oral formulations are projected to experience the fastest growth, with a CAGR of 6.0% during the forecast period.

Rising demand for innovative drug delivery systems and growing healthcare needs worldwide are key drivers.

Competitive Landscape:

In the medication formulation industry, major players are employing methods such as advanced product launches through approvals and mergers and acquisitions. The major businesses are concentrating on working with the research institutes to gain a competitive edge in the marketplace.

A definitive merger agreement between Bristol Myers Squibb and Turning Point Therapeutics was signed on June 20, 2022. This acquisition will expand BMS’s selection of oncology drugs because Turning Point Therapeutics is a precision oncology company that is still in the clinical development stage.

AstraZeneca introduced The Evusheld long-acting antibody combo to the public on March 20, 2022. For the pre-exposure prophylaxis (prevention) of COVID-19 in a sizable population, it has received authorization in Europe.

Key Companies Profiled:

AstraZeneca plc.

Bristol-Myers Squibb

Eli Lilly and Company

Gilead Sciences, Inc.

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

AbbVie Inc.

Boehringer Ingelheim International GmbH

F. Hoffmann-La Roche AG

Johnson & Johnson

3M Company

Bayer AG

Teva Pharmaceuticals Industries Ltd.

Amgen, Inc.

Sanofi SA

GlaxoSmithKline plc

Boston Scientific Corporation

Gerresheimer AG

Nimbus Therapeutics

Antares Pharma, Inc.

IDEAYA Biosciences, Inc.

Key Market Segments Covered in Drug Formulation Industry Research:

By Dosage Form:

Oral formulations

Tablets

Immediate Release

Modified Release

Chewable

Effervescent

Capsules

Hard Gelatin Capsules

Softgel Capsules

Others

Powders & Granules

Lozenges & Pastilles

Gummies

Others

Parenteral formulations

Solutions

Suspensions

Emulsions for injection or infusion

Powders for injection or infusion

Gels for injection implants

Topical formulations

Pastes

Ointments and oils

Creams, lotions, and foams.

Gels, tinctures, and powders

Sprays and patches

Inhalation formulations

Pressurized Metered Dose Inhaler

Dry Powder Inhaler (DPI)

Nebulizer

By Indication:

Infectious Diseases

Cancer

Cardiovascular Diseases

Diabetes

Respiratory Diseases

Central Nervous System Disorders

Autoimmune Diseases

Gastrointestinal Diseases

Musculoskeletal Disorders

Dermatological Disorders

Other

By End User:

Big pharma

Small & Medium Size Pharma

Biotech Companies

By Region:

North America

Latin America

Europe

South Asia

East Asia

Oceania

The Middle East and Africa (MEA)

[creativeera]

The Ascending Potential of Liposome Drug Delivery Market is Driven by Nanotechnology

Liposome drug delivery refers to the technology enabling entrapment of therapeutic or cosmetic agents in liposomes which are artificially prepared vesicles made of lipid bilayers. Advances in nanotechnology have allowed for the development of liposomes as drug carriers that can fuse with cell membranes and deliver encapsulated drug payload at target sites within the body.

The liposome drug delivery market is estimated to be valued at USD 5,482.2 Mn in 2024 and is expected to reach USD 9,935.6 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.

Key Takeaways Key players operating in the liposome drug delivery market are Gilead Sciences, Inc., Luye Pharma Group, Ipsen Biopharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Acuitas Therapeutics, LIPOSOMA B.V., Takeda Pharmaceutical Company Limited, Taiwan Liposome Company, Ltd., Endo International, and Jazz Pharmaceuticals plc. These players are focusing on R&D activities to develop novel liposome formulations for various therapeutic applications. The growing demand for targeted drug delivery systems is expected to drive the demand for liposome drug delivery globally. Liposomes allow for selective delivery of encapsulated drugs to the intended site of action while preventing damage to healthy tissues. This reduces systemic side effects and enhances therapeutic efficacy. The Liposome Drug Delivery Market Growth is also witnessing significant expansion in emerging economies. Factors such as the growing geriatric population, rising investments in healthcare infrastructure, and increasing focus on nanomedicines are expected to boost market revenue in Asia Pacific, Latin America, and Middle East & Africa over the forecast period. Market Key Trends The use of advanced analytical techniques such as microfluidics and supercritical fluid technologies for production of liposomes is one of the key trends in the industry. These techniques allow for precision encapsulation of drugs, reproducible quality, and large scale manufacturing of liposomes. Liposome Drug Delivery Market Size and Trends promises to enhance drug delivery capabilities and facilitate commercialization.

Porter’s Analysis Threat of new entrants: High capital requirements and stringent regulations create barriers for new entrants in the liposome drug delivery market. Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternative drug delivery technologies. Bargaining power of suppliers: Suppliers have moderate to high bargaining power due to their differentiated technologies and expertise required for liposome production. Threat of new substitutes: Technological improvements in alternative drug delivery systems like nanoparticle drug delivery pose a threat. Competitive rivalry: The liposome drug delivery market witnesses high competition due to the presence of major players. Geographical Regions North America holds the largest share in the liposome drug delivery market owing to the presence of major players and early adoption of advanced drug delivery technologies. The rising prevalence of cancer and increasing R&D investments have also boosted the regional market. The Asia Pacific region is expected to grow at the fastest pace during the forecast period. Factors such as growing healthcare expenditure, increasing awareness regarding advanced treatments, and expansion of key players into emerging markets will drive the liposome drug delivery market in the Asia Pacific region.

Get more insights on Liposome Drug Delivery Market

Discover the Report for More Insights, Tailored to Your Language

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[techninja]

Market Forecast: Predicting Growth Trajectory and Opportunities in the Softgel Capsules Industry

Unveiling the Lucrative Realm of Softgel Capsules Market

Introduction

In the ever-evolving landscape of pharmaceuticals, softgel capsules have emerged as a pivotal player, revolutionizing drug delivery systems. These encapsulated wonders offer a myriad of benefits, ranging from enhanced bioavailability to improved patient compliance. At the heart of this innovation lies a bustling market, brimming with opportunities and challenges alike. In this comprehensive guide, we delve deep into the dynamics of the softgel capsules market, unraveling its nuances and potential for growth.

Understanding Softgel Capsules

What Are Softgel Capsules?

Softgel capsules represent a sophisticated dosage form characterized by a gelatin shell enclosing liquid or semi-solid fillings. This versatile encapsulation technique facilitates the administration of various pharmaceuticals, including oils, suspensions, and solutions, with unparalleled precision and efficacy.

Key Advantages

Enhanced Bioavailability: The unique composition of softgel capsules promotes rapid absorption and bioavailability of active ingredients, ensuring optimal therapeutic outcomes.

Improved Stability: The hermetic seal of softgel capsules shields delicate compounds from environmental factors, prolonging shelf life and maintaining product integrity.

Ease of Swallowing: Unlike traditional dosage forms, softgel capsules boast a sleek, easy-to-swallow design, enhancing patient comfort and compliance.

Market Landscape

Growth Trajectory

The softgel capsules market has witnessed exponential growth in recent years, fueled by advancements in pharmaceutical technology and rising consumer demand for convenient drug delivery systems. With an expanding geriatric population and escalating prevalence of chronic diseases, the market shows no signs of slowing down.

Key Players

Leading pharmaceutical companies are capitalizing on the burgeoning demand for softgel capsules, leveraging innovative formulations and strategic partnerships to gain a competitive edge. From multinational giants to niche players, the market is teeming with diverse stakeholders vying for market share.

Market Segmentation

By Product Type

Gelatin-based Softgel Capsules: Traditional gelatin formulations continue to dominate the market, owing to their versatility and cost-effectiveness.

Non-gelatin Softgel Capsules: With growing concerns regarding religious and dietary restrictions, non-gelatin alternatives such as plant-based and fish-derived capsules are gaining traction among health-conscious consumers.

By Application

Pharmaceuticals: The pharmaceutical sector accounts for the lion's share of softgel capsules usage, driven by the need for targeted drug delivery and enhanced patient adherence.

Nutraceuticals: The burgeoning nutraceutical industry relies on softgel capsules to encapsulate vitamins, minerals, and dietary supplements, catering to wellness-conscious consumers seeking convenience and efficacy.

Market Dynamics

Drivers

Technological Advancements: Continuous innovation in encapsulation technology, coupled with the advent of novel excipients, is expanding the horizons of the softgel capsules market.

Consumer Preference for Oral Dosage Forms: The growing preference for oral dosage forms over conventional tablets and injections is fueling the demand for softgel capsules, driving market growth.

Challenges

Regulatory Hurdles: Stringent regulatory frameworks governing pharmaceutical manufacturing pose a significant challenge for market players, necessitating compliance with stringent quality standards and guidelines.

Price Volatility of Raw Materials: Fluctuations in the prices of gelatin and other raw materials used in softgel capsules production can impact profit margins and operational efficiency, posing a challenge for manufacturers.

Future Outlook

The future of the softgel capsules market appears promising, buoyed by ongoing research and development efforts aimed at enhancing product efficacy and safety. With increasing investments in precision medicine and personalized healthcare, softgel capsules are poised to play a pivotal role in shaping the future of drug delivery systems.

Conclusion

In conclusion, the softgel capsules market represents a dynamic and thriving sector within the pharmaceutical industry, driven by innovation, consumer demand, and regulatory developments. As market dynamics continue to evolve, staying abreast of emerging trends and opportunities is paramount for industry stakeholders seeking to capitalize on this lucrative market segment.

[luckydige45]

The global drug formulation market is valued at USD 1.75 trillion in 2023 and is projected to reach a value of USD 2.95 trillion by 2032 at a CAGR of 6.05% between 2023 and 2032

[cmipooja]

Veterinary Excipients Market: Growing Demand for Animal Healthcare Products Drives Market Growth

The global Veterinary Excipients Market is estimated to be valued at US$ 241.64 million in 2022 and is expected to exhibit a CAGR of 7.5% over the forecast period of 2022-2030, as highlighted in a new report published by Coherent Market Insights. This market is witnessing high growth owing to the increasing demand for animal healthcare products. Market Overview: Veterinary excipients are inactive substances added to animal healthcare products to enhance their stability and efficacy. These excipients play a crucial role in the formulation of various drugs, vaccines, and nutritional supplements for animals. They help in improving product quality, enhancing drug delivery, and ensuring safety for animal consumption. The need for veterinary excipients is driven by the growing pet population worldwide and the rising prevalence of animal diseases. These factors contribute to the growth of the veterinary excipients market. Market Key Trends: One key trend driving the growth of the veterinary excipients market is the increasing adoption of companion animals. Pet ownership has been on the rise globally, with more people seeking companionship from pets. This trend has led to a higher demand for veterinary healthcare products, including drugs and supplements. Moreover, pet owners are becoming more conscious about their pet's health and are willing to spend on quality healthcare products. This increasing adoption of companion animals is creating lucrative opportunities for the veterinary excipients market. For example, in the United States, the pet population has been increasing steadily, with around 67% of households owning at least one pet. This growing pet population has resulted in a surge in demand for veterinary healthcare products, driving the need for veterinary excipients. PEST Analysis: Political: The veterinary excipients market is influenced by regulatory policies and guidelines related to animal healthcare products. Governments across the globe have implemented strict regulations on the manufacturing and distribution of veterinary drugs and supplements to ensure their safety and efficacy. Economic: The economic factors influencing the veterinary excipients market include GDP growth, disposable income, and consumer spending on pet healthcare. Economic stability and increasing pet ownership contribute to the market's growth. Social: The rising awareness about animal health and the increasing trend of pet humanization are driving the demand for veterinary healthcare products. Pet owners are now more willing to invest in high-quality products for their pets' well-being. Technological: Advancements in pharmaceutical manufacturing processes and drug delivery systems have led to the development of innovative veterinary healthcare products. These technological advancements have improved the efficacy and convenience of administering medications to animals. Key Takeaways: - The Global Veterinary Excipients Market Demand is expected to witness high growth, exhibiting a CAGR of 7.5% over the forecast period. The increasing demand for animal healthcare products, driven by the growing pet population, is the primary driver of market growth. - North America is expected to dominate the veterinary excipients market due to the high pet adoption rate and increased spending on animal healthcare. Europe is also a significant market player, with strict regulations ensuring product safety. - Key players operating in the global veterinary excipients market include BASF SE, Croda Health Care, JRS Pharma, Lipoid GmbH, Azelis, U.K. Vet Chem, Gattefoss, Synergy API, Anzchem, and Vantage.

[transmutationisms]

Do you have a perspective on why stimulants aren’t currently widely prescribed as weight loss drugs? Im guessing it’s related to it being a ‘controlled substance’ and ‘scary drug’ but drug marketing in pursuit of pharmaceutical profits is pretty powerful… I wonder why I haven’t seen (effective?) efforts to try to ‘overhaul’ the image of stimulants as only associated with “addiction”, “hyperactive children”, finance bros, and “lazy adults”.

I know vyvanse is also prescribed for binge eating but I get the sense most people are unaware of that. I tried many stimulants and I had the most rapid and “easy” (found food repulsive) weight loss on vyvanse. Granted all of the many prescribed stimulants I’ve tried all greatly suppress my appetite.And I’ve seen it described as a benefit by some people who have it prescribed for adhd (I understand why people do and I sometimes see it as a very depressing benefits because lack of food security despite). Binge eating disorder and prescribing for general weight loss aren’t too far from each other in the fatphobic society we live in but I guess I’m curious how it hasn’t had the ozempic treatment already/ when will it happen. People already look down of folks who can’t function by society’s standards in certain contexts and I see that similarity in how people talk about people who take ozempic for weight loss (admonishing and a moral failure).

stimulants absolutely still are prescribed for weight loss lol, in addition to Vyvanse for 'binge eating' (v unreliable diagnosis that many people receive when they are in fact dealing with subjective loss of control around food as a direct result of restrictive behaviours...) there's also Desoxyn (methamphetamine) and Phentermine (a substituted amphetamine), which are both still FDA-approved for short-term weight management. and yes that's Phentermine as in half of fen-phen. you also have to keep in mind that off-label prescribing is hard to track but is probably still occurring at not-insignificant rates (i know it happens with Ephedra and Clenbuterol, for example). and then there are also patients who use stimulants for weight loss without a doctor's knowledge, either by obtaining them on the black market or by simply getting a doctor to prescribe them for something else.

anyway in regards to pharma marketing strategies i think there are a few things going on here:

weight loss has never actually been the sole market for these drugs, nor was it the first. amphetamine was first synthesised in 1929; it was put into asthma inhalers almost immediately and by the late 30s was being sold as a kind of generalised wellness-producing drug, used by, for instance, college students as a 'pep pill'. the Allies used quite a bit of amphetamine in WWII to keep soldiers alert (the US military was still doing this in Iraq and Afghanistan in the 2000s; afaik they have not stopped this practice). by the late 50s stimulants were also marketed as pick-me-ups for unhappy housewives and for a dizzying array of depression 'subtypes' (postpartum, old age-related, disability-related) and 'modern miseries' (atomic anxiety, economic and political unrest). it wasn't until the 50s and 60s that stimulants really started to be marketed as diet pills, with 'overeating' configured as a symptom of depression. even those formulations also had other use markets: professional athletes, for example. i'm sure pharma companies would love to have the stimulant dominance they once did in weight loss, but it's not really necessary in order to move product: these days the ADHD diagnosis will generally do the job just fine. nicolas rasmussen's book On Speed has more on this history.

speaking of the ADHD diagnosis, i have observed that in the last two or so decades, it has increasingly been invoked in bioessentialist narratives of either 'chemical imbalances' (usually dopamine, norepinephrine) or distinct 'neurotypes' that are said to cause, worsen, or be susceptible to 'overeating', which can therefore be treated by the use of stimulant drugs. i strongly suspect an effect here is that 'overeating', weight gain, or 'obesity' are de facto being used as diagnostic criteria for ADHD, or for other psychiatric diagnoses considered to have high overlap in behavioural presentation. this is not dissimilar to the formulation in the 60s of 'overeating' as a result of depression; in both cases the narrative elides the appetite-suppressant effects of stimulants and presents them as aiding with weight loss by treating an underlying bio/psychiatric pathology. an interesting historical note here is that Adderall is simply a rebrand of the second-gen formulation of the weight-loss drug Obetrol.

presently, weight loss is largely marketed using the language of health rather than aesthetics. although pharma companies are certainly not morally above lying, i do think it would be a tough pill to swallow (pun intended) if they tried to convince anyone that a stimulant prescription is part of this sort of 'wellness' scene. that could change in the future, ofc; these perceptions and associations are socially and historically contingent. in the US even as recently as the 90s, people were definitely still presenting fen-phen as health-promoting (tautologically, because it caused weight loss!), at least until the valve disease scandal.

glp-1 agonists like ozempic are, i think, getting a lot of extremely credulous coverage, from both the medical establishment and health journalists, that is obfuscating the fact that they basically also work by suppressing the appetite. whether it is 'healthier' to do this with a substance that alters endocrine function than to do it with a substance that acts on adrenergic receptors is unclear to me. certainly there are many 'side effects' of the glp-1 agonists that are simply the results of rapid / significant weight loss (fatigue, weakness, osteoporosis, hair loss, gallstones, 'ozempic face', &c). that a process that causes these things can be marketed as health-promoting is a whole other topic lol. but i think the perception of the glp-1 agonists as healthful weight-loss agents has to do with certain misunderstandings of diabetes, metabolism, and body weight, as well as a degree of... not quite blackboxing, but something adjacent, on the part of pharma companies in their promotional materials. which is to say, it wouldn't surprise me if, in the future, people looked back at glp-1 agonists as also being risky drugs to use for weight loss, and only being worth using in specific, limited circumstances.

[toastyslayingbutter]

"Hoping to avoid the white cast, heaviness and greasiness common in many sunscreen products available in U.S. drugstores, some Americans, including Representative Alexandria Ocasio-Cortez of New York, have taken matters into their own hands, opting for sunscreens manufactured abroad. In a recent interview, the congresswoman said she toggled between Bioré in the summer and Beauty of Joseon in the winter — two Asian brands that employ active ingredients not approved for use in the United States.

“The technology is very sophisticated,” Ms. Ocasio-Cortez said. “You don’t feel like you have a layer of sunscreen on, and it kind of just feels like you’re putting on a moisturizer in that sense, which makes it easier to use.”

While sunscreen is regulated as a cosmetic in major skin-care hubs like South Korea, Japan and the European Union, in the United States, it falls under the purview of the Food and Drug Administration. Any drug product marketed to American consumers must be approved by the F.D.A., and because sunscreen “makes a drug claim” — namely, that it can prevent sunburn, decrease the risk of skin cancer and mitigate early skin aging — the agency regulates it as an over-the-counter drug.

The last time the Food and Drug Administration approved new active ingredients for use in sunscreens was more than two decades ago, and at times it can feel as if the rest of the world has surpassed the United States in the development of new sunscreen formulations and protocols. Skin-care influencers on TikTok and Instagram are in a near-constant state of frenzy over exciting new products and innovations that are nowhere to be found on American shelves. Currently there are 14 sunscreen filters approved for use by the F.D.A. The European Union employs more than 30.

Frustrated by what seems to be a wealth of more exciting options for sun protection overseas, skin-care-conscious Americans have been quick to point the finger at the F.D.A. for the delay in approving new active ingredients. But according to Ms. Ocasio-Cortez, the agency is not to blame for the holdup, at least not entirely.

“I think the assessment here is that Americans need sunscreen, and they have sunscreen,” she said. “Are there other avenues that we can use in order to kind of break through this standstill? Yeah.”

Congress has begun a “preliminary, early process” of examining what a better approval procedure might look like, she said: a way that pushes the manufacturers of sunscreen filters to do the appropriate research and development to submit drug information to the F.D.A. for approval.

“I also think it’s very important that we maintain a level of rigor around safety,” Ms. Ocasio-Cortez said. “We want to make sure this is not about advocating for the deregulation of these filters.”

[dailycharacteroption]

Class Feature Friday: Pharmacology Field of Study (Biohacker Field of Study)

(art by ianllanas on DeviantArt)

While there are plenty of biohackers that are not medical doctors, focused on biochemistry above all else, but all in some way do deal with drugs and the careful application thereof in some way.

None can truly be said to specialize in such medicines more so than experts in pharmacology.

Pharmacology is the study of how drugs and other substances affect the body, which is by no means a cut and dry field. Different body types and quirks of biology in just one species are enough to make certain drugs ineffective or outright dangerous to use on certain individuals, to say nothing of a far future where multitudes of sapient species exist.

These pharmacologists might be doctors practicing direct medicine, or they might be researchers trying to make breakthroughs to help treat all manner of disease and conditions, not to mention find useful enhancements or even recreational compounds.

Of course, more villainous biohackers might be trying to perfect truth serums or that make the mind more pliable.

No matter their practice, these biohackers boast familiarity which can heal allies and debilitate foes.

The booster for this field is a coagulant, preventing and stopping excess bleeding.

Their inhibitor, however, is a minor hallucinogen, slowing and inhibiting the target as they react to false stimuli.

Meanwhile, their breakthrough is a combination painkiller and antiemetic that helps ward off those effects or even reverse them, even if they normally didn’t allow for resistance.

Now, obviously biohackers with this field will likely load up on all manner of medicinals, as well as healing and protective serums, with perhaps a side of combat drugs and poisons, particularly those based on drugs formulated in labs, such as sedatives and the like. Meanwhile, pretty much any theorem is a good choice for them, but especially those that deal with medicine and and drugs, such as Medication Mastery, Treatment Mastery, Hotbox, Accelerated Metabolism, Adaptive Metabolism, First Aid Expert, Improved Treat Condition, Energetic Booster, Greater Treat Condition, and so on.

If there was ever such a thing as a “generic” option for the biohacker, this would be it. After all, a class that specializes in injecting foes and allies with various drugs having a specialization in drugs is fairly generic. That being said, it does lend itself quite well for removing debuffs and debuffing foes in kind, so don’t think it’s boring or useless just because it’s not as exotic as other options.

With their focus on medicinal and other types of drugs, These characters could easily be doctors, drug dealers, military combat drug formulators, and so on. Anywhere that living creatures exist, there will be a need for an understanding of how their bodies work and how they react to substances.

While old and marked by their emotional connection to sorrow, Bikayi has been a pediatrician for many years, helping the young ones of the colony grow up happy and healthy. However, the venerable moyishuu has a long history they don’t like to talk about, one involving a pharmaceutical corporation and their less than ethical experiments.

The mining world of Kobidar IV has been quarantined due to a nullsoul plague. This nanomachine disease turns androids into something akin to zombies, albeit fast, aggressive, and able to reconfigure to bypass obstacles. On the surface, a group of uninfected androids and dwarven doctors work desperately to engineer an antivirus program that can prevent further infection and potentially put a stop to the infected.

Rumor has it a new street drug called Astral has entered the market, supposedly causing out of body experiences. However, none yet realize that the secret of the compound was spread by daemons seeking to take advantage of souls in their vulnerable state and devour them.

[dykesbites]

do you have migraines or headaches, and are you poor, have shitty/no insurance, doctors who won't listen to you, or just don't want to waste hundreds of dollars on an appointment? well, i went to a neurologist and received this piece of paper which i probably paid way too much for, so you can have it for free.

American Headache Society Complementary and Integrative Medicine Section: Patient Education Kit for Migraine (Recommended Supplements for Migraine Prevention) <- link

the supplements may or may not work, but either way this should save you time and money. you can buy these supplements at most drug stores or online.

below the cut i'm adding a transcript of the pdf in case the link breaks.

stuff my doctor told me:

i should take magnesium glycinate, riboflavin, and CoQ10

magnesium glycinate should be taken at bedtime

didn't recommend feverfew for me, can't remember why

if these supplements don't help, the next step is prescription meds which include Nortriptyline, Topamax, or Emgality

Nortriptyline is an anti-depressant, if you're already on an anti-depressant then don't take this

Topamax is an anti-seizure med also used to prevent migraines. it can make birth control pills less effective

Emgality is administered once a month with a self-administered shot (something like an epi pen). this is what my doctor recommended I take if the supplements don't work. it specifically targets the migraine receptor, so it has very few side effects

PDF transcript:

AHS Complementary and Integrative Medicine Section: Patient Education Kit for Migraine

Recommended Supplements for Migraine Prevention Dietary supplements are commonly used for the prevention of migraine. The recommended supplements have all been studied and found to be effective in the prevention of migraine. If you are pregnant or have other medical conditions, please check with your physician about whether you should take these.

Magnesium

Mechanism: Important in energy production, muscle and nerve function, and may play a role in cortical spreading depression, which is an underlying migraine mechanism.

Evidence: Two large randomized controlled trials found magnesium to be beneficial for migraine prevention.

Dose: 600mg per day. Some people prefer to start at a lower dose to ensure tolerability. Formulations include magnesium oxide, magnesium sulfate, magnesium citrate (better absorbed than oxide or sulfate), and magnesium glycinate (less likely to cause diarrhea than other formulations)

Side effects: May cause soft stools or diarrhea, but could help constipation.

Riboflavin (Vitamin B2)

Mechanism: Involved in mitochondrial energy production, which may play a role in migraine

Evidence: Five clinical trials, including one large randomized controlled trial, have shown positive effect on migraine.

Dose: 400mg per day

Side effects: Turns urine bright yellow/orange and may cause diarrhea.

Feverfew

Mechanism: Parthenolide, the active ingredient, may prevent migraine through its vascular smooth relaxation and anti-inflammatory properties.

Evidence: Four out of six studies showed benefit for migraine prevention

Dose: 50-300mg twice daily

Side effects: Nausea, bloating, and mouth ulcers. Feverfew can cause uterine contractions and is not recommended during pregnancy.

Coenzyme Q10 (CoQ10)

Mechanism: Involved in energy production and helps maintain mitochondrial integrity.

Evidence: Two randomized controlled trials showed benefit over placebo.

Dose: 300mg daily (can be split into 150mg twice a day)

Side effects: Insomnia, fatigue, nausea, or diarrhea.

Other Supplements Butterbur demonstrated benefit for migraine in two large randomized controlled studies; however; preparations may contain pyrrolizidine alkaloids which are toxic to the liver. Due to safety concerns, butterbur was removed from the market in Europe and is currently not recommended. Melatonin and the combination of folic acid/B6/B12 have mixed results for migraine prevention.

Reference: Rajapakse T, Pringsheim T. Nutraceuticals in migraine: A summary of existing guidelines for use. Headache. 2016;56(4).

[ausetkmt]

Pain killer: an empire of deceit and the origin of America's opioid epidemic

Pain killer: an empire of deceit and the origin of America's opioid epidemic

In Pain Killer, Barry Meier breaks new ground in his decades-long investigation into the opioid epidemic.

Between 1999 and 2017, an estimated 250,000 Americans died from overdoses involving prescription painkillers, a plague ignited by Purdue Pharma’s aggressive marketing of OxyContin. Families, working class and wealthy, have been torn apart, businesses destroyed, and public officials pushed to the brink. Meanwhile, the drugmaker’s owners, Raymond and Mortimer Sackler, whose names adorn museums worldwide, made enormous fortunes from the commercial success of OxyContin.   In Pain Killer, Barry Meier tells the story of how Purdue turned OxyContin into a billion-dollar blockbuster. Powerful narcotic painkillers, or opioids, were once used as drugs of last resort for pain sufferers. But Purdue launched an unprecedented marketing campaign claiming that the drug’s long-acting formulation made it safer to use than traditional painkillers for many types of pain. That illusion was quickly shattered as drug abusers learned that crushing an Oxy could release its narcotic payload all at once. Even in its prescribed form, Oxy proved fiercely addictive. As OxyContin’s use and abuse grew, Purdue concealed what it knew from regulators, doctors, and patients.   Here are the people who profited from the crisis and those who paid the price, those who plotted in boardrooms and those who tried to sound alarm bells. A country doctor in rural Virginia, Art Van Zee, took on Purdue and warned officials about OxyContin abuse. An ebullient high school cheerleader, Lindsey Myers, was reduced to stealing from her parents to feed her escalating Oxy habit. A hard-charging DEA official, Laura Nagel, tried to hold Purdue executives to account.   In Pain Killer, Barry Meier breaks new ground in his decades-long investigation into the opioid epidemic.

He takes readers inside Purdue to show how long the company withheld information about the abuse of OxyContin and gives a shocking account of the Justice Department’s failure to alter the trajectory of the opioid epidemic and protect thousands of lives. Equal parts crime thriller, medical detective story, and business exposé, Pain Killer is a hard-hitting look at how a supposed wonder drug became the gateway drug to a national tragedy.

From the Pulitzer Prize–winning New York Times reporter who first exposed the roots of the opioid epidemic and the secretive world of the Sackler family behind Purdue Pharma, Pain Killer is the celebrated landmark story of corporate greed and government negligence that inspired the Netflix limited series Painkiller.   “This is the book that started it all. Barry Meier is a heroic reporter and Pain Killer is a muckraking classic.”—Patrick Radden Keefe, author of Empire of Pain New York Times Book Review Editors’ Choice

[bhushans]

Beyond Diagnosis: Exploring Global drug formulation market

The demand for global drug formulation market size is anticipated to expand at a 5.6% compound annual growth rate (CAGR). The market for pharmaceutical formulations was estimated to be worth US$ 1.58 trillion in 2022 and is projected to reach US$ 2.87 trillion by 2032. The study projects that over the projection period, oral formulations will develop exponentially, with a compound annual growth rate (CAGR) of 6.0%.

The demand for innovative medication formulations that provide efficient clinical care and an economical manufacturing method is rising as medicines continue to enhance people's quality of life. Biologics have become a well-liked therapeutic alternative for managing chronic illnesses.

Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-15755

The emergence of biosimilars has forced pharmaceutical companies to stay competitive by lowering their costs or coming up with new ideas, which has sparked innovation in the biologics industry. As of right now, the FDA has approved 37 biosimilars; nevertheless, in 2019, the number of biosimilars approved climbed by 65% while the total number of biosimilar medications available in the US expanded by 157%. Nonetheless, as evidenced by the widespread use of biosimilars over the past 13 years in Europe, payers, providers, and manufacturers anticipate that biosimilar competition will lead to ongoing price reductions. The amount of treatment alternatives available for a given disease or condition will incentivize manufacturers to lower the price of their products, which will propel the drug formulation market's rise in the upcoming years.

Key Takeaways:

The oral formulation is estimated to have a 44.6% market value share by the end of 2032 and to increase at a 6.0% CAGR over the forecast period.

Based on various indications, central nervous system diseases account for 14.1% of the market in 2021 and are expected to dominate throughout the projection period.

In terms of end-user, the big pharma corporations are predicted to grow at a 5.1% CAGR in the next years.

North America is expected to be the leading region by the conclusion of the forecast period, with a value share of 48.1%.

“Growing prevalence of chronic disorders and Rising needs for novel drug formulation in the pharmaceutical sectors is expected to witness the growth of Drug Formulation Market over the forecast period,”says an analyst of Future Market Insights.

Market Competition

Key Players:

AstraZeneca plc.

Bristol-Myers Squibb

Eli Lilly and Company

Gilead Sciences, Inc.

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

AbbVie Inc.

Boehringer Ingelheim International GmbH

F. Hoffmann-La Roche AG

Johnson & Johnson

3M Company

Others

The drug formulation industry’s pharmaceutical and biotech businesses are concentrating on leveraging market potential by implementing mergers and acquisitions strategies. The trend continues as a result of the effective marketing campaign of novel and innovative drug formulation portfolios following strategic partnerships, acquiring their place in the market. The key techniques employed by the manufacturers to extend their business units and customer bases in both developed and emerging economies include strategic collaborations, mergers and acquisitions, production capacity expansions, and expanding product sales.

For instance,

The COVID-19 vaccine was developed by Pfizer with the assistance of Sanofi in 2021, and Bayer and CureVac formed a complex cooperation to distribute 160M doses of the vaccine by 2022.

The German mRNA CDMO AmpTec was acquired by Millipore Sigma, the life science division of Merck KGaA. This strengthened offerings across the mRNA value chain, especially for MilliporeSigma, which already supplies lipids to Pfizer-BioNTech for their COVID-19 vaccines. Lipids are the main mode of delivery for mRNA therapeutics.

More Insights Available:

North America is one of the largest pharmaceutical formulations market due to the high prevalence of chronic diseases, such as diabetes and cardiovascular diseases, and the presence of a large number of pharmaceutical companies. The United States is the largest market in the region, with a well-established healthcare system, high healthcare spending, and favorable regulatory policies.

Key Segments:

By Dosage Form:

Oral formulations

Tablets

Immediate Release

Modified Release

Chewable

Effervescent

Capsules

Hard Gelatin Capsules

Softgel Capsules

Others

Powders & Granules

Lozenges & Pastilles

Gummies

Others

Parenteral formulations

Solutions

Suspensions

Emulsions for injection or infusion

Powders for injection or infusion

Gels for injection implants

Topical formulations

Pastes

Ointments and oils

Creams, lotions, and foams.

Gels, tinctures, and powders

Sprays and patches

Inhalation formulations

Pressurized Metered Dose Inhaler

Dry Powder Inhaler (DPI)

Nebulizer

By Indication:

Infectious Diseases

Cancer

Cardiovascular Diseases

Diabetes

Respiratory Diseases

Central Nervous System Disorders

Autoimmune Diseases

Gastrointestinal Diseases

Musculoskeletal Disorders

Dermatological Disorders

Other

By End User:

Big pharma

Small & Medium Size Pharma

Biotech Companies

[cmisayali]

Throat Lozenges: Alleviating Sore Throats New Findings Offer Promising Relief

What are Throat Lozenges?

Cough drop are medicated candy-like tablets that are designed to provide quick relief to coughs or sore throats. They dissolve slowly in the mouth, allowing the ingredients to coat and soothe the throat. Key Ingredients in Throat Lozenges

Throat Lozenges generally contain one or more of the following active ingredients that work to relieve throat irritation : Anesthetics - Such as benzocaine or phenol aid in numbing throat pain. They work topically to reduce throat sensitivity. Anti-inflammatory Agents - Like menthol or eucalyptus oil work by reducing inflammation. They promote mucus drainage to clear congestion. Demulcents - Materials like honey or glycerin coat the throat lining. They protect it from further irritation when swallowing or coughing. Antibiotics - Lozenges containing tetracycline are occasionally prescribed for bacterial throat infections. They treat specific infections. How do Throat Lozenges Work?

When a throat lozenge dissolves in the mouth, its active ingredients are released. They coat and numb the throat, reducing discomfort. Specific ingredients may also reduce swelling or treat infections : - Anesthetics temporarily numb painful areas, blocking throat pain signals. - Anti-inflammatory agents decrease swelling in irritated throat tissues. This lessens pain. - Demulcents form a protective film over inflamed areas, shielding them from further irritation. - Antibiotics kill or limit bacterial growth if a strep throat is present. This resolves the underlying cause. The slow dissolving nature also allows the throat to be continuously coated for 30-60 minutes, enhancing relief during that period. Using Cough drop Effectively

For best results, cough drop should be used as per product instructions. Some general tips on their effective use include: - Allow the lozenge to dissolve slowly in the mouth, rather than chewing or swallowing it whole. This ensures maximum coating of the throat. - Suck on the lozenge for at least 15-20 minutes for the ingredients to take maximum effect before swallowing any remnants. - Use lozenges at the first signs of a sore throat, rather than waiting for severe pain. Early action provides prompt symptom relief. - Lozenges work best for recently developed throat irritations. See a doctor for persistent or worsening pain. - Drink plenty of fluids while using lozenges to keep the throat moist. Water is recommended over acidic juices. - Lozenges containing local anesthetics provide temporary pain relief. Seek medical help if symptoms persist beyond a few days. Popular Throat Lozenge Brands

Some globally recognized throat lozenge brands offering effective temporary relief include: - Halls: Known for its menthol and eucalyptus flavors, it soothes and fights germs. - Strepsils: Contains phenol as an active ingredient. It aims to relieve pain from streptococcal sore throats. - Thayers: A honey-based lozenge brand formulated to moisturize and protect the throat naturally. - Chloraseptic: Branded lozenges utilizing benzocaine as an oral anesthetic to numb throat pain. - Cough Drops: A variety of flavored cough drop and drops by Ricola and Fishermans Friend. - Biotene: Specialized lozenges and mouthwashes for dry mouth relief alongside sore throat symptoms. In Summary, cough drop are widely available over-the-counter at pharmacies. They offer a convenient, drug-free way to temporarily relieve common throat afflictions. Using them properly under medical guidance helps maximize symptom comfort.

Get More Insights On - Throat Lozenges

Discover the Report for More Insights, Tailored to Your Language.

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[soniez]

India's Pharma Industry – The Leading Companies You Need to Know

India's pharmaceutical industry stands as a global powerhouse, contributing significantly to the world's supply of medicines and pharmaceutical products.  The country's ability to produce high-quality, affordable medicines has earned it the title of "Pharmacy of the World."  As the industry continues to grow and innovate, several companies have emerged as leaders in the market.  For Centurion HealthCare Pvt. Ltd., understanding the landscape of the top pharma companies in India provides insights into the key players driving the industry's success.

The Rise of the Pharmaceutical Industry in India

The pharmaceutical industry in India has seen exponential growth over the past few decades.  From generic drug manufacturing to complex biotechnological innovations, Indian pharma companies have made substantial contributions to global healthcare.  This growth can be attributed to several factors, including a skilled workforce, robust research and development infrastructure, and supportive government policies.

Key Players in India's Pharma Industry

The landscape of the pharmaceutical industry in India is populated by numerous companies, each contributing to various segments of the market.  Here are some of the top pharmaceutical companies in India that are leading the charge:

1.   Sun Pharmaceutical Industries Ltd.

As the largest pharmaceutical company in India, Sun Pharma is renowned for its diverse product portfolio, including generics, branded generics, specialty medicines, and active pharmaceutical ingredients (APIs).  The company has a significant global presence and continues to expand its footprint through strategic acquisitions and partnerships.

2.   Dr. Reddy's Laboratories

Dr. Reddy's is a major player in the global generic pharmaceutical market.  Known for its strong focus on research and development, the company offers a wide range of pharmaceuticals and biotechnology products.  Their commitment to quality and innovation has solidified their position as one of the best pharmaceutical companies in India.

3.   Cipla Ltd.

Cipla has been at the forefront of providing affordable medicines for over eight decades.  The company specializes in respiratory, cardiovascular, anti-retroviral, and anti-infective therapies.  Cipla's dedication to healthcare accessibility and its significant contributions to global health initiatives make it a top pharmaceutical company in India.

4.   Lupin Limited

Lupin is a leading pharmaceutical company known for its focus on complex generics and specialty drugs.  The company's strong presence in both developed and emerging markets has earned it a place among the top 10 pharmaceutical companies in India.  Lupin's investment in R&D and its broad therapeutic portfolio are key drivers of its success.

5.   Aurobindo Pharma

Aurobindo Pharma is recognized for its extensive range of generic formulations and APIs.  The company's robust manufacturing capabilities and strategic global presence have made it one of the top pharmaceutical companies in India.  Aurobindo's commitment to innovation and quality continues to propel its growth.

6.   Zydus Cadila

Zydus Cadila, a leading pharmaceutical company, offers a wide range of healthcare solutions, including small molecules, biologics, biosimilars, and vaccines.  The company's integrated operations and strong research capabilities have established it as a key player in the pharma industry in India.

7.   Glenmark Pharmaceuticals

Glenmark is a global research-led pharmaceutical company known for its focus on innovation in the fields of dermatology, respiratory, and oncology.  The company's strong pipeline of new chemical entities and biosimilars underscores its position as one of the best pharmaceutical companies in India.

8.   Torrent Pharmaceuticals

Torrent Pharma is a major player in the cardiovascular and central nervous system therapeutic areas.  The company's strategic acquisitions and focus on niche segments have helped it become one of the top pharmaceutical companies in India.  Torrent's commitment to quality and patient-centric approach is evident in its product offerings.

9.   Biocon Ltd.

Biocon is India's largest biopharmaceutical company, specializing in biologics and biosimilars.  The company's focus on affordable innovation and its significant contributions to chronic disease management make it a leader in the pharmaceutical industry in India.  Biocon's global partnerships and strong R&D capabilities are key to its success.

10. Cadila Healthcare (Zydus)

Cadila Healthcare, also known as Zydus, is a prominent player in the Indian pharma industry, offering a wide range of healthcare solutions.  The company's innovative approach and comprehensive product portfolio have positioned it among the top 10 pharmaceutical companies in India.

The Role of Pharma Manufacturing Companies in India

Pharma manufacturing companies in India play a crucial role in the global supply chain of medicines.  These companies not only produce high-quality generics but also invest heavily in research and development to bring new and innovative drugs to the market.  The efficiency and scale of Indian pharma manufacturing are key factors in the country's ability to provide affordable medicines worldwide.

Finding the Best Pharma Companies Near You

For those searching for "pharma companies near me," it's important to recognize the regional presence of leading pharmaceutical companies.  Many top pharma companies in India have established manufacturing and research facilities in various parts of the country, ensuring widespread access to their products and services.

Centurion HealthCare Pvt. Ltd.  – A Leading Player in the Industry

Centurion HealthCare Pvt. Ltd. is an emerging name in the Indian pharmaceutical landscape.  As a medicine manufacturing company in India, Centurion HealthCare is dedicated to providing high-quality pharmaceutical products across various therapeutic categories.  The company's commitment to innovation, quality, and patient care positions it among the best pharma companies in India.

The Future of the Pharmaceutical Industry in India

The future of the pharmaceutical industry in India looks promising, with continued growth driven by innovation, increasing healthcare needs, and expanding global reach.  Indian pharma companies are expected to play a pivotal role in addressing global health challenges, developing new treatments, and ensuring the availability of affordable medicines.

Conclusion

India's pharmaceutical industry is a dynamic and rapidly evolving sector, with numerous companies leading the way in innovation, quality, and global healthcare contributions.  From established giants like Sun Pharma and Dr. Reddy's to emerging leaders like Centurion HealthCare Pvt. Ltd., the top pharmaceutical companies in India are making significant strides in improving healthcare outcomes worldwide.

As the industry continues to grow, these companies will remain at the forefront of pharmaceutical advancements, ensuring that India retains its position as a global leader in medicine production and innovation.  Whether you are looking for the best pharma company in India or seeking reliable pharmaceutical companies in India, the landscape is rich with options that exemplify excellence and commitment to health.

For Centurion HealthCare Pvt. Ltd., being part of this esteemed group of pharma companies in India is a testament to its dedication to quality, innovation, and patient care.  As the industry moves forward, Centurion HealthCare is poised to continue its growth and contribute to the global healthcare landscape, solidifying its place among the best pharmaceutical companies in India.

[pharma-franchise01]

The Future Of Derma PCD Franchise Company In India: Trends and Opportunities

Dermatology is one of the major branches of medical science. Looking at the shining present and bright future of PCD Derma franchise company in India. Many pharma companies have started to own the Derma PCD franchise company in India. 

With the high rise in the API index in every city in India, we know that pollution is tempering our health inside out. From lung infection to skin diseases heavy pollution and unclean surroundings are common in all cities. Skin allergies, fungal infections, acne, pimples and dark spots are just a few consequences of living in a polluted environment. Unhygienic and unhealthy eating is also one of the main reasons for building skin-related issues. Tempering the food with artificial colouring and other agents leads to skin irritation and allergies for many people.  

People try to treat these problems by buying common derm products from any medical shop. And this panic buying resulted in high sales of derma products. Many entrepreneurs grabbing this opportunity and starting a derma franchise company in India.

The Present of a Derma Franchise Company in India

Nowadays people often see dermatologist doctors for the treatment of their skin-related ailments. Thus it increases the sale of dermatological products in the market, and with the high demand big opportunities start lining up. 

Several derma products are available in the market, most of them are prescription free and some have to be prescribed by the derma doctor because of their drug formulation. Combining both, derma products have a huge market in India. We know the obsession of Indians with skin care products.

Talking about the present for the derma franchise company in India it's bright and most pharma companies “operating in derma products“ are thriving. See around yourself and mind the shelves of medical shops, their display shelves are full of derma products. 

 The Future of a Derma Franchise Company in India

Right now, is the best time to own a derma franchise company in India. Many reputed PCD derma franchise companies in India are running with throttle to meet the market expectations, they are also supporting other pharma companies by providing their franchises of derma products.

From the distribution of franchises to third-party manufacturers all are sailing the boat without paddling. That is why the future of the derma market and derma franchises are even brighter minding the increment in skin-related issues. 

Rising opportunities with the expansion of the Derma market 

Capitalising on the Derma market expansion is the best option for finding an astounding and resilient Derma PCD franchise company in India. It is the right time to partner with the Derma PCD franchise company because they not only provide their franchise to compete in the Derma market but also provide tools to leverage the opportunity for breaking into the market. 

Derma PCD Franchise company in India provides its franchisee the right to market and distribute its product without any intervention. You may find the Medliva Franchise perfect for your company because they have a wide range of derma products.

This Derma franchisor can provide complete marketing and promotional support to franchisees. We have achieved heights in the pharma industry. Hence partnering and taking a derma franchise company in India could be a game-changing choice for your business growth.   

[luckydige45]

The global drug formulation market is valued at USD 1.75 trillion in 2023 and is projected to reach a value of USD 2.95 trillion by 2032 at a CAGR of 6.05% between 2023 and 2032

[ask-a-vetblr]

Hopping on the Mirataz question, do you have any idea why we don't have transdermal versions of Gabapentin or Trazodone? I'm a (new) vet tech who has worked in critical care and emergency, and it feels like even though it may work at reduced efficiency, it would be helpful in long term hospitalization cases to avoid repeated force-pilling for stressed animals.

Sueanoi here,

For seizure control by medicine injection, we have diazepam available. It's not the same, but the intended result of reducing anxiety and seizure control works.

Gabapentin has an additional effect of nerve-related analgesia, while at hospital, if the animal is resistant to pilling to the point that it's distressful, I'd prescribe another injection analgesia, or even fentanyl patch if needed.

The downside is, pills are often the cheapest form of medications available in the market. Using injections long term can accumulate cost to hazardous levels to the owner's wallet. (With well communication, this can still be a choice available if the owner is willing to pay)

Also, if animals are well familiarized with pilling, it is often the LESS stressful method of medication, comparing to getting restrained and injected with needles twice a day. (So please, owners, train your pets to take pills early in life.)

gettingvetted here.

Sueanoi practices in Asia, so I wanted to give a North American perspective here.

Transdermal formulations of pretty much anything is available these days. Find the right compounding pharmacy (typically Wedgewood or Roadrunner, but there are plenty of others including human pharmacies) and they can make you just about anything in transdermal form.

Here’s the issue - FDA approval of 99.9% of drugs (and 99.9% of studies surrounding drugs) is either for oral or injectable forms. There is no guarantee that transdermal formulations work in the same way as the drug’s other forms (or any guarantee that they work at all).

Plus, there is a veeeeery gray area surrounding compounded drugs (those that are taken from their original form and turned into another form, like an oral capsule/tablet into a liquid or transdermal), at least in the US: - Technically speaking, I am allowed to compound a drug for a patient if its approved form is unsuitable for the patient (for example, the only doses available are too large or the approved drug is mixed with another drug that I don’t want to use on the patient, like codiene with tylenol). - It is illegal to compound a drug for price purposes, for instance. - It is *technically* illegal to compound a drug if there is anything else that’s approved for the desired use and we haven’t tried that yet. For example if I want sedation for a vet visit in a cat, and the owner has tried but can’t give gabapentin capsules, I am technically supposed to have them try giving acepromazine, trazodone, etc prior to compounding gabapentin into a liquid or transdermal for the owner. - It is also illegal to compound drugs in bulk to keep in the hospital and then dispense individual doses of said compounded drugs to patients. So in a case like an ER, it would be illegal to order a bunch of transdermal gabapentin and trazodone to have on hand for individual patients. Each compounded drug is supposed to be used on one patient and one patient alone.

Those last two items are pretty much ignored by everyone... nobody is going to make a cat owner with difficulty pilling their cat, try acepromazine or trazodone pills prior to just prescribing them the gabapentin in an easier formulation. And pretty much every hospital has *something* sitting around that is compounded in bulk and dispensed in individual doses to patients (for example my hospital keeps compounded ponazuril and pimobendan in stock). Even the FDA has come out and said “listen we are just trying to keep randos from compounding and illegally selling potentially dangerous formulations of different medications, we’re not going to come after you for prescribing liquid gabapentin or keeping a stock of compounded dewormer in your hospital.”

So, long story short - it’s doable, but technically illegal and probably doesn’t work as well as you want it to.